Dr. Nishant Raizada

Are drugs like Ozempic, Mounjaro, and Wegovy the ultimate solution to the obesity epidemic, or are they just a short-term trend? In this episode, we sit down with our endocrinologist Dr. Nishant Raizada, Professor & Head, Department of Endocrinology and Diabetes, to separate science from sensationalism.

We break down how GLP-1 receptor agonists actually work in the brain and body, who should and shouldn't be taking them, the hidden dangers of muscle loss, and their surprising benefits for fatty liver disease, heart health, and diabetes remission.

Key Takeaways & Highlights:

• The Brain Science: How GLP-1s hijack hunger, block dopamine "reward hits" from junk food, and even reduce alcohol cravings.
• The "Ozempic Bride" Trend: Why using GLP-1s for quick-fix, short-term cosmetic weight loss can trigger rapid weight rebound and ruin your metabolism.
• Muscle Loss vs. Fat Loss: The critical rule to preventing muscle loss while on weight-loss medications (and why protein + resistance training are non-negotiable).
• Beyond Weight Loss: How dual and triple agonists (like Tirzepatide & Retatrutide) are actively reversing advanced fatty liver disease (MASLD) and protecting kidney function.
• Diabetes Remission: Can GLP-1s cure Type 2 Diabetes? The reality of stopping medication vs. long-term lifestyle changes.